Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

Li, XJ; Li, B; Wang, M; Fang, M; Lou, JF; Liu, JR; Chen, H; Ding, YH

Ding, YH (通讯作者)，First Hosp Jilin Univ, Phase 1 Clin Trail Ctr, 1 Xinmin St, Changchun 130021, Peoples R China.

BIODRUGS, 2023; ():

Abstract

Background and ObjectiveQX006N is a novel, humanized, IgG4 kappa monoclonal antibody targeting IFNAR1, developed for the treatment of systemic lupus e......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索